glp-1 risks Benefits and of Receptor Agonists Outlined Why do patients stop GLP-1

Funny enough, he had never actually seen a Gila monster up close until after the drug designed to mimic Gila venom was FDA approved

Amylin primarily acts through the AP-NTS-hypothalamic axis to induce satiety and delay gastric emptying, whereas GLP-1 influences hindbrain and mesolimbic circuits to suppress reward-driven feeding and enhance insulin secretion

If side effects persist beyond four weeks without improvement, consult your doctor

Theme 3: Off-Label Use in Type 1 Diabetes (T1D) Although GLP-1s are not approved for people with T1D, some individuals with T1D are using them off-label, particularly if they live with obesity, strong insulin resistance, or significant post-meal blood sugar spikes

One KFF analysis estimates that roughly 36 million non-elderly Americans with employer coverage alone meet BMI criteria for a GLP-1, while only a small fraction are taking one today, which points to large latent demand constrained by cost

November 24, 2023